Time for Australia to increase take away doses in opioid agonist treatment.
Int J Drug Policy
; 127: 104420, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38614016
ABSTRACT
Opioid Agonist Treatment is the cornerstone of minimising harms related to opioid use, however its uptake is limited by a tightly regulated and stigmatising treatment environment. The COVID-19 pandemic necessitated relaxation of some treatment restrictions, with global evidence pointing to more patient-centred care in this time. In light of local evidence to support the safety of increased access to takeaway doses and a precedent set by the Substance Abuse and Mental Health Administration, we recommend adoption of the Australian Interim Medication Assisted Treatment of Opioid Dependence guidance in Australia.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Tratamiento de Sustitución de Opiáceos
/
COVID-19
/
Analgésicos Opioides
/
Trastornos Relacionados con Opioides
Límite:
Humans
País/Región como asunto:
Oceania
Idioma:
En
Revista:
Int J Drug Policy
Asunto de la revista:
SAUDE PUBLICA
/
TRANSTORNOS RELACIONADOS COM SUBSTANCIAS
Año:
2024
Tipo del documento:
Article